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Abstract
To systematically review the evidence to determine the clinical outcomes and the important methodological quality features 
of interventional studies on adults with non-inflammatory multi-joint pain (MJP). Systematic search of published and unpub-
lished literature using the databases: AMED, CINAHL, MEDLINE, EMBASE, psycINFO, SPORTDiscus, PEDro, OpenGrey, 
the EU Clinical Trials Register, World Health Organization International Clinical Trial Registry Platform, ClinicalTrials.
gov and the ISRCTN registry (search: inception to 19th October 2017). All papers reporting the clinical outcomes of non-
pharmacological interventions for people with non-inflammatory MJP were included. Studies were critically appraised using 
the Downs and Black Critical Appraisal and the TIDieR reporting checklists. Data were analysed using a Best Evidence 
Synthesis approach. From 3824 citations, four papers satisfied the eligibility criteria. Three studies reported outcomes from 
multidisciplinary rehabilitation programmes and one study reported the findings of a spa therapy intervention. All interven-
tions significantly improved pain, function and quality of life in the short-term. There was limited reporting of measures for 
absenteeism, presenteeism and psychosocial outcomes. The evidence was ‘weak’, and due to a lack of controlled trials, there 
is limited evidence to ascertain treatment effectiveness. Design consideration for future trials surround improved reporting of 
participant characteristics, interventions and the standardisation of core outcome measures. There is insufficient high-quality 
trial data to determine the effectiveness of treatments for non-inflammatory MJP. Given the significant health burden which 
this condition presents on both individuals and wider society, developing and testing interventions and accurately reporting 
these, should be a research priority.
Registration PROSPERO (CRD42013005888).
Keywords Pain · Arthritis · Therapeutics · Clinical Trial · Research design
Introduction
Musculoskeletal pain presents a significant clinical chal-
lenge and is associated with a substantial health and social 
burden [1, 2]. The majority of patients with musculoskeletal 
complaints experience pain at more than one joint [3, 4]. 
Non-inflammatory multi-joint pain (MJP) represents a com-
plex mix of osteoarthritis, back pain and soft tissue disorders 
[5]. It is associated with increased disability, depression and 
lost work productivity [6]. People with MJP may have a 
median of six painful joints [5] and evidence indicates that 
an increasing number of painful joints is associated with 
poorer physical and mental statuses [7, 8], increasing the 
risk of restrictions on both activity and social participation. 
The costs associated with MJP are significantly greater than 
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those associated with low back pain alone, which costs the 
NHS approximately £1700 million annually [2].
Both clinical care and research have traditionally focused 
on treating single joint pain and disability [9], failing to rec-
ognize the impact of MJP on treatment choices and outcomes 
[10]. Whilst a recent survey suggests that the majority of 
general practitioners now treat MJP concurrently rather than 
focusing on a single joint [11], there remains uncertainty on 
how this should be operationalized, and what interventions 
should be used. To this end, the National Institute for Health 
and Care Excellence (NICE) recommended in their osteoar-
thritis guidelines [12] that trials to investigate interventions 
for the management of MJP should be a research priority.
Currently, only one systematic review has examined 
interventional trials for people with MJP [9], concluding 
that there is limited evidence to guide treatment choice. 
However, whilst all studies in this review investigated the 
effectiveness of an intervention package designed for people 
with MJP, in practice, participants were recruited into these 
trials with single joint pain in the hip, knee or hand joints 
[13–15] rather than targeting people with co-existing pain 
in two or more joints. Furthermore, this review paper was 
based only on studies which were multidisciplinary in deliv-
ery (two or more different health professional groups), were 
delivered in primary or community care settings, and were 
required to incorporate NICE recommended core treatments 
[12]. Consequently, it remains unclear whether outcomes for 
these interventions would differ with a true MJP population, 
and if there are other interventions which may be supported 
for this population when delivered by specific professional 
groups in secondary and primary care.
The purpose of this review is, therefore, to: (1) address 
this uncertainty and examine the current literature to deter-
mine the effectiveness of different interventions for people 
with non-inflammatory MJP, and (2) identify key research 
design features which should be considered when designing 
future trials on people with non-inflammatory MJP.
Methods
Search strategy
The primary search was of published literature searching the 
databases: AMED, CINAHL, MEDLINE, EMBASE, psy-
cINFO, SPORTDiscus and PEDro. Secondary search strate-
gies included searching the unpublished and grey literature 
databases: OpenGrey, the EU Clinical Trials Register, World 
Health Organisation International Clinical Trial Registry 
Platform (ICTRP), ClinicalTrials.gov, and the ISRCTN reg-
istry. All databases were searched from database inception 
to 19th October 2017, and performed by one reviewer (TS). 
The search strategy for the MEDLINE search (via Ovid) is 
presented in Table 1. This was modified for each individual 
database. The reference lists from all potentially eligible 
papers and review papers were reviewed. All corresponding 
authors from each included study were contacted to review 
the search results to identify any additional studies which 
may have been initially omitted.
Eligibility criteria
Studies were eligible if they satisfied the following criteria.
Design
Randomized or non-randomized trials presenting clini-
cal outcomes for one or more defined interventions for the 
population of interest. Data on the location of intervention, 
who delivered it and the frequency to which it was provided 
was the minimum information required to be defined as an 
intervention. We excluded all basic science research and 
animal studies.
Population
Adults (16 years and over) with concurrent pain located at 
two or more joints e.g. ankle and hip. In accordance with 
Raja et al. [5] definition of MJP, we defined a joint-site as 
a region e.g. hand, foot, rather than by individual ‘small’ 
Table 1  MEDLINE search strategy
1. joint diseases/
2. arthropathy.ti,ab
3. arthritis/
4. esp osteoarthritis/
5. (pain$ adj3 (dual$ widespread or many)).ti,ab
6. (pain$ adj3 (number or one or two or three or four) adj3 (site$ or 
location$ or area$ or joint$)).ti,ab
7. (pain$ adj3 (multi$ or multi?joint or multi?site or multi?focal)).
ti,ab
8. ((multi$ or widespread or dual$) adj5 (musculo?skelet$ or joint$) 
adj5 (pain$ or problem$)).ti,ab
9. generalized osteoarthritis.ti,ab
10. generalized pain.ti,ab
11. widespread pain.ti,ab
12. musculoskeletal pain.ti,ab
13. widespread musculoskeletal pain.ti,ab
14. multisite musculoskeletal pain.ti,ab
15. multiple pain sites.ti,ab
16. regional pain.ti,ab
17. fibromyalgia/
18. fibromyalgia.ti,ab
19. OR/2–18
20. AND/1,19
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joints such as 1st carpometacarpal and 5th proximal inter-
phalangeal joint. It could include combinations of joint dis-
orders including osteoarthritis, back pain and tendinopathy. 
Pain could be a self-reported and/or physical examination-
based diagnosis, but we excluded studies where MJP was 
diagnosed solely by radiological investigation. We excluded 
studies where participants reported pain in two or more 
locations without specific joint involvement such as fibro-
myalgia, myofascial pain, or widespread pain originating 
from soft-tissue/connective tissue disorders. “Methods” 
or “Results” section required to clearly indicate concur-
rent involvement of two or more joints. If the term “and/
or” for joint involvement was used in the methodology, the 
“Results” section must have described concurrent involve-
ment of two or more joints. e.g. ‘ankle and hip joint pain’ or 
‘five percent of participants had pain in two joints’. However, 
we included studies which recruited people with MJP and 
non-MJP where the population with MJP was specifically 
identified and results for the cohort were reported separately, 
or where 90% or over of that cohort were diagnosed with 
MJP. We excluded all studies where participants had inflam-
matory arthropathies such as rheumatoid arthritis.
Intervention
Any non-pharmacological interventions or care pathways 
for the population of interest were included. This, therefore, 
included exercise and physical activity interventions, pacing 
and behavior modification interventions, psychological inter-
ventions, self-management programmes and device/assisted 
technologies. Packages of care which included one or more 
of these interventions were included. Interventions which 
comprised both a pharmacological and non-pharmacological 
treatment were included when the principle intervention was 
non-pharmacological and the pharmacological treatment an 
adjunct. We did not place a restriction on the frequency or 
intensity of an intervention, the location of delivery or who 
(which professionals) delivered the intervention.
Comparison
Any intervention or non-treatment control group was eligible 
as a comparator. Papers which did not include a comparator 
group (i.e. pre-post test design) were included.
Outcome
The a priori primary outcome measure was pain at 6-months 
post-commencement of the intervention. This could have 
been measured as part of a tool such as the Western Ontario 
and McMaster University Arthritis Index score (WOMAC) 
[16] or as a numerical rating scale (NRS) or visual analogue 
scale (VAS) pain score.
Secondary outcome measures were:
• Pain measured at other time-points,
• Physical function measured with tools such as the 
WOMAC [16], Knee Injury and Osteoarthritis Outcome 
Score (KOOS) [17] or Oswestry Disability Index scores 
(ODI) [18],
• Health-related quality of life measured with instruments 
such as the Short Form-12 (SF-12) [19], SF-36 [20], or 
the EQ-5D-5L [21],
• Anxiety and depression measured with tools such as the 
Hospital Anxiety and Depression scale (HADS) [22],
• Fear avoidance and kinesphophia measured with tools 
such as the Fear Avoidance Beliefs Questionnaire [23] 
and Tampa Scale of Kinesphobia [24],
• Self-efficacy measured with tools such as the General 
Self-Efficacy Scale [25],
• Work absenteeism and presenteeism.
Assessment intervals were defined as immediate-term 
(0–6 weeks), short-term (more than 6 weeks–3 months), 
mid-term (more than 3–12 months) and longer-term (more 
than 12 months).
Publication
We included all papers which reported eligible trials, irre-
spective of date of publication, language of publication, or 
where (geographically) the study was conducted.
Study identification
Three reviewers (RR, BD, CC) independently reviewed the 
titles and abstracts of all search results using the defined eli-
gibility criteria. Full-texts for all papers deemed potentially 
eligible were gathered, and re-reviewed by the three review-
ers (RR, BD, CC) for full eligibility. All papers satisfying 
the criteria and agreed between two or more reviewers were 
included.
Data extraction
Data extracted included: population characteristics defini-
tion of MJP; participant: age, gender, joint pain location, 
number of joint pain sites, BMI, SES group; country of 
trial origin; sample size; location of intervention delivery 
(i.e. primary or secondary care); intervention constituents 
i.e. treatment types, dose and frequency, self-management/
home management programme, co-interventions; control 
intervention constituents; outcome measures and follow-
up intervals assessed; length of follow-up; clinical findings 
including effect size and intervention fidelity. All data were 
collected independently onto a pre-defined data extraction 
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table by three reviewers (BD, CC, TS). Any disagreements 
were resolved through discussion.
Critical appraisal
To assess the quality of the current evidence and key design 
features for trials of people with MJP, all included studies 
were critically appraised using the Downs and Black Check-
list [26]. This is a reliable and valid critical appraisal tool 
for non-randomised and randomised controlled trials [26]. 
It includes 27-items assessing: reporting, external validity, 
internal validity and power. To assess the reporting of study 
interventions we used the 12-item TIDieR checklist [27]. 
This assesses: intervention reporting by asking questions 
on: why, what (materials), what (procedure), who provided, 
how, where, when and how much, tailoring, modifications, 
how well (planned), how well (actual) [27]. The assessment 
for both checklists was independently performed by two 
reviewers (BD, CC).
Data synthesis
Study heterogeneity was assessed by examining the data 
extraction table. Due to between-trial variability in cohort 
participant’s characteristics, interventions (experimental 
and control) and study design/processes, a meta-analysis 
was inappropriate [28]. Consequently, a narrative analysis 
of the data was performed using a Best Evidence Synthesis 
approach [29] where studies were graded as ‘strong’, ‘mod-
erate’ or ‘weak’ as a judgement made by the three reviewers 
(CC, BD, TS) based on the Downs and Black assessment and 
the TIDieR evaluation.
Results
Search strategy
A summary of the search results is presented as Fig. 1. A 
total of 3824 citations were identified of which 126 were 
deemed potentially eligible and reviewed at full-text level. 
The reasons for exclusion included papers not reporting 
interventional studies (n = 102) or they did not include 
patients who met the a priori definition of MJP (n = 16), 
or were study protocols (n = 4). Of the full-text papers 
reviewed, four satisfied the eligibility criteria and were 
included.
Characteristics of included studies
The characteristics of the included studies are presented in 
Table 2. Three papers reported the findings from observa-
tional pre-test/post-test investigations [6, 10, 30], whilst one 
paper reported a randomised controlled trial (RCT) [31]. 
Three studies presented data on multidisciplinary team 
(MDT) programmes for people with MJP [6, 10, 31]. Erol 
et al. [30] reported the clinical findings of a spa therapy 
intervention.
Two studies characterised and termed their cohorts as 
people with ‘generalised osteoarthritis’ [30, 31]. Lillefjell 
et al. [6] and Moradi et al. [10] termed this group ‘chronic 
musculoskeletal pain’ but provided specific definitions of 
joint involvement, thereby meeting the eligibility of MJP for 
this review. In all four studies, the definition of joint pain in 
two or more joints were specified (Table 2). Moradi et al. 
[10] and Lillefjell et al. [6] recruited people with both sin-
gle and MJP. However, Moradi et al. [10] reported the find-
ings of single- and MJP separately, whilst 94% of Lillefjell 
et al’s [6] cohort were MJP and, therefore, met the eligibility 
criteria.
Quality assessment
A summary of the critical appraisal results is presented in 
Table 3. The randomised controlled trials presented with a 
moderate risk of bias, whilst the non-randomised controlled 
trials presented with ‘low’ quality evidence. In both, the 
TIDieR checklist assessment (Table 4) highlighted recur-
rent limitations in intervention reporting. The included 
studies were consistently poor in reporting materials and 
participant’s role within and towards the intervention and its 
delivery (Item 3; 25%), the description of the intervention’s 
activities (Item 4; 25%), the dosage (Item 8; 0%), the adap-
tion or modification of the intervention (Item 9 and 10; 0%) 
and only Cuperuset al [31] reported the fidelity (Item 12; 
25%). Based on the quality assessment, seven key research 
design considerations where identified for consideration 
when designing future trials for people with MJP. These are 
presented in Table 5.
Intervention 1: Multi‑disciplinary 
programme
Three studies presented data on MDT programmes in people 
with MJP [6, 10, 31].
Pain
Two studies of moderate [31] and weak [6] evidence 
were available to support a significant decrease in pain at 
short-term follow-up. Cuperus et al. [31] reported a sig-
nificant decrease in pain by 3.2 points at 6-week follow-
up. Lillefjell et al’s [6] MDT programme reported a mean 
decrease in pain by 3.8 points (p < 0.05) at 5-week follow-
up. Moderate evidence was available from Cuperus et al. 
Rheumatology International 
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[31] of no statistically significant change in pain score 
for their telephone-based intervention (6 week difference: 
0.96; 1-year: 0.76).
There was weak evidence from one study [10] to sup-
port a significant decrease in pain at mid-term follow-up 
(6 months). Moradi et al. [10] reported a mean decrease of 
1.4 points (p < 0.001) for their dual-joint pain group, and 
1.2 points for their MJP group (p < 0.001).
Two studies of moderate [31] and weak [6] evidence 
were available to support a significant decrease in pain 
at long-term follow-up. Cuperus et al. [31] reported a 
2.8 point decrease at 1-year (p < 0.05) for their face-to-
face MDT intervention and Lillefjell et al. [6] 5.7 points 
(p < 0.01) at long-term (57 week) follow-up.
Physical function
Two studies of moderate [31] and weak [6] quality were 
available to evaluate physical function. Cuperus et al. [31] 
reported a statistically significant increase in physical func-
tion for their cohort who received the face-to-face and tele-
phone-based MDT interventions at 6 weeks (mean difference 
form baseline: 2.25 and 1.58, respectively; p < 0.05). Simi-
larly, Lillefjell et al. [6] reported a mean difference in COOP/
WONCA daily activity assessment but only by 0.10 points 
and 0.23 points at 5 and 57 weeks follow-up (p < 0.001).
There was weak evidence from one study [10] to sup-
port improvements at mid-term follow-up. Moradi et al. [10] 
reported a mean increase in SF-36 physical function of 17.1 
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points specifically in their dual-joint pain cohort and 9.2 
points in their MJP cohort at 6-month follow-up (p < 0.001).
There was conflicting evidence from one study of moder-
ate [31] and another of weak quality [6] regarding functional 
outcomes in the longer-term. Cuperus et al. [31] reported 
neither intervention provided statistically significant findings 
from baseline for this measure at 12 months (SF-36 physical 
function: mean difference from baseline: 1.58 points and 
1.13 points; p > 0.05). Lillefjell et al. [6] reported statistically 
significant improvements in physical function at longer-term 
follow-up assessments.
Health‑related quality of life
One study [31] of moderate evidence supported improve-
ments in quality of life using the EQ-VAS. Cuperus et al. 
[31] reported a significant improvement in quality of life 
in both intervention groups at 6-week follow-up (p < 0.05), 
the magnitude of improvement being greater for the face-to-
face group (mean difference: 8.43 points) compared to the 
telephone-based intervention group (mean difference 5.22 
points). At 12 months, this difference remained in the face-
to-face group (mean difference 6.59; p < 0.05), but not in the 
telephone-based intervention group (mean difference 3.73).
Anxiety and depression
One study [6] of weak evidence assessed anxiety and depres-
sion at short and long-term follow-up using the HADS. 
Lillejjfell et al. [6] reported that both anxiety (p < 0.05) and 
depression (p < 0.01) both significantly decreased at the 5 
and 57-week follow-up intervals in this MDT intervention. 
This was not a large change. There was a mean reduction 
in anxiety by 0.18 points at 5 weeks, and 0.9 at 57 weeks. 
Similarly, there was a mean reduction in depression by 0.44 
points at 5 weeks, and 0.95 at 57 weeks.
Fear avoidance and kinesophophia
There was moderate evidence from one study [31] showing 
there was no statistically significant difference in kinesopho-
bia in either the face-to-face MDT intervention or telephone-
based intervention at 6 weeks or 12 months (p > 0.05).
Self‑efficacy
There was moderate evidence from one study [31] reporting 
no statistically significant difference in self-efficacy when 
evaluated using the General Self-Efficacy Questionnaire in 
either the face-to-face MDT intervention or telephone-based 
intervention at 6 weeks or 12 months (p > 0.05).
Missing outcomes
No studies reported findings of fear avoidance, absenteeism 
or presenteeism for either of the three MDT intervention 
papers.
Table 4  TIDieR checklist for 
interventional reporting
Checklist items: Provide the name or a phrase that describes the intervention. Describe any rationale, the-
ory, or goal of the elements essential to the intervention. Describe any physical or informational materi-
als used in the intervention, including those provided to participants or used in intervention delivery or in 
training of intervention providers. Provide information on where the materials can be accessed (e.g. online 
appendix, URL). Describe each of the procedures, activities, and/or processes used in the intervention, 
including any enabling or support activities. For each category of intervention provider (e.g. psychologist, 
nursing assistant), describe their expertise, background and any specific training given. Describe the modes 
of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the interven-
tion and whether it was provided individually or in a group. Describe the type(s) of location(s) where the 
intervention occurred, including any necessary infrastructure or relevant features. Describe the number of 
times the intervention was delivered and over what period of time including the number of sessions, their 
schedule, and their duration, intensity or dose. If the intervention was planned to be personalised, titrated 
or adapted, then describe what, why, when, and how. If the intervention was modified during the course of 
the study, describe the changes (what, why, when, and how). Planned: If intervention adherence or fidelity 
was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, 
describe them. Actual: If intervention adherence or fidelity was assessed, describe the extent to which the 
intervention was delivered as planned
TIDieR checklist items Total per 
study 
(%)1 2 3 4 5 6 7 8 9 10 11 12
Cuperus [31] 1 1 0 0 1 1 0 0 0 0 1 1 50
Erol [30] 1 1 1 1 1 0 1 0 0 0 1 0 58.3
Lillefjell [6] 1 1 0 0 0 0 0 0 0 0 0 0 16.7
Moradi [10] 1 1 0 0 0 1 0 0 0 0 0 0 25
Total per item (%) 100 100 25 25 50 50 25 0 0 0 50 25
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Intervention 2: Spa therapy
One study presented outcomes of a spa therapy intervention 
for people with MJP [30]. Using a Best Evidence Synthesis 
approach, the outcomes from this study were classified as 
‘weak’ evidence.
Pain
Whilst there was a statistically significant improvement in 
pain from baseline to post-treatment (4.8 to 3.7; p < 0.01), 
this was not statistically significant at mid-term (8 months) 
follow-up (4.8 to 4.5; p = 0.15).
Physical function
There was a statistically significant improvement in physi-
cal function when measured using the WOMAC subsection 
from baseline to post-treatment (19.5–15.2; p < 0.01). This 
was not statistically significant at mid-term (8 months) fol-
low-up (19.5–19.7; p = 0.76). The Oswestry Disability Index 
decreased in the immediate-term (3 weeks) from 25.4 to 
20.8 (p < 0.01) and at the mid-term but only differed by two 
points (p = 0.04).
Health‑related quality of life
Immediate-term (3-week commencement of treatment), 33% 
reported an acceptable symptom state (achieved PASS). 
Mid-term (8-month post-commencement of treatment) this 
increased to 75%. There was a significant increase in the 
Modified Health Assessment Questionnaire (p = 0.03), Rou-
tine Assessment of Patient Index Data (p < 0.01), EQ-5D 
(0 = 0.02), EQ VAS (p < 0.01) and Patient Global Assess-
ment (p < 0.01). However, none of these were statistically 
significant at the mid-term (final) assessment (p > 0.05).
Other measures
No data was reported on measures including anxiety and 
depression, fear avoidance, kinesphophia, self-efficacy, 
absenteeism or presenteeism measured.
Discussion
Face-to-face MDT rehabilitation interventions may reduce 
pain, increase function and improve symptom control for 
people with MJP, and spa-based treatments may result in 
short-term reductions in symptoms but have limited longer-
term benefits. However, the data were of insufficient quality 
to provide conclusive evidence of effectiveness because of 
underpowered cohorts, and limitations in reporting of the 
diagnostic criteria of MJP, intervention procedures or out-
come measures used. It is, therefore, not possible to form 
recommendations on what interventions or packages of care 
should be used for people with MJP.
Lack of detailed reporting of interventions is a com-
mon limitation in rehabilitation trials [32]. Consequently, 
interventions which have demonstrated effectiveness can-
not be readily adopted into clinical practice, and research-
ers are unable to replicate, develop and synthase research 
findings. Only one study in this review involving an MDT 
programme [31] satisfied the criteria for completeness of 
intervention reporting according to the TIDieR checklist 
[15]. Detailed reporting is particularly important for the tri-
als of MJP where the interventions proposed are frequently 
packages of care which are multi-componented, and offer 
a range of potential interventions, dosage and settings for 
delivery. Accordingly, researchers and journal reviewers/edi-
tors should be mindful of this when reporting and preparing 
papers for publication to ensure future trials better describe 
these interventions.
Conducting this review was complicated by the lack of 
standardised diagnostic criteria and terminology for people 
with MJP. This may be partly attributed to the nature of MJP 
as it represents a complex mix of osteoarthritis, back pain 
and soft tissue disorders [5]. The most commonly adopted 
term in the current literature is ‘generalised osteoarthritis’ 
[30, 31], but other terms include ‘widespread musculo-
skeletal joint pain’ [3, 6, 10], ‘multi-joint site pain’ [9] and 
‘multi-site joint pain’ [5, 33]. Furthermore, a range of dif-
ferent radiological and clinical diagnostic criteria have been 
used to define MJP [30]. However, there is still no consensus 
on how to define or classify MJP [34, 35]. Adoption of an 
agreed term to define this population and use of standardised 
diagnostic criteria for MJP for future trials will be impera-
tive to improve reporting and implementation.
Outcome assessment of people with MJP can be particu-
larly challenging because of disparate clinical symptoms 
including pain, fatigue, atrophy and psychosocial traits, and 
also the varied number and location of joints affected by pain 
[5] and functional restrictions [1]. This review highlights the 
current lack of standardisation in outcome measures used in 
MJP trials. Given the variability in population characteristics 
and presentation, routine use of outcome measures which 
examine the global impact of MJP should be considered, 
such as the HAQ Disability Index (HAQ-DI) validated by 
Cuperus et al. [1]. Moreover, given that MJP can affect peo-
ple across the adult life-span, routine inclusion of outcome 
tools which assess work-related productivity (presenteeism 
as well as absenteeism) such as the Work Productivity and 
Activity Impairment Questionnaire [36] would also be valu-
able for future trials.
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This study has two limitations of note. First, due to the 
limited evidence, it was not possible to answer the origi-
nal research question on the effectiveness of interventions 
for MJP. Second, due to the variability in diagnostic crite-
ria used and poor study reporting, the review team found 
the identification of eligible papers a challenge. Strategies 
including regular discussions on eligibility, member-check-
ing and consensus adjudicators were used to overcome this. 
Nonetheless, until there is an agreed diagnostic terminology 
used to classify this population, future systematic reviewers 
may face similar difficulties. Given the limitations in report-
ing the diagnostic criteria for MJP and the interventions 
which have been investigated, we have developed research 
design considerations (Table 5) to aid the future develop-
ment of trials which are urgently required to better treat this 
clinical population.
In conclusion, there is insufficient literature to make 
clinical recommendations on the treatment of people with 
MJP. The current evidence-base is limited by study design, 
diagnostic classification, selection of standardized outcome 
measures and reporting of study interventions. Given the 
significant health burden which MJP has on both the indi-
vidual and wider society, developing and testing interven-
tions to improve symptom management of this condition 
is a research priority. The methodological considerations 
highlighted on design and reporting should be considered 
when developing such trials.
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